Literature DB >> 22805547

The usefulness of the consensus clinical diagnostic criteria in Brugada syndrome.

Andrea Sarkozy1, Gaetano Paparella, Tim Boussy, Ruben Casado-Arroyo, Yoshinao Yazaki, Gian-Battista Chierchia, Carlo De Asmundis, Fatih Bayrak, Mehdi Namdar, Sergio Richter, Josep Brugada, Pedro Brugada.   

Abstract

BACKGROUND: Consensus statements were proposed for the diagnosis of Brugada syndrome (BS). The clinical diagnostic criteria were defined as documented ventricular fibrillation or ventricular tachycardia (VT), family history of sudden cardiac death at <45 years, diagnostic ECGs of family members, inducibility of VT during electrophysiological study, syncope or nocturnal agonal respiration. The clinical validation of these criteria is still missing. Methods and results 280 patients (41 ± 18 years, male: 168 pts) with diagnostic coved type I ECG were included. Consensus clinical diagnostic criteria were present in 244 (87%) patients (40 ± 18 y, 142 males). In 36 pts (13% of the 280 pts, 51 ± 12 years, 27 males) consensus clinical diagnostic criteria were not met. Nine patients (25%) presented with spontaneous type I ECG. Ten of the 36 patients (28%) had a history of atrial fibrillation and 13 (36%) had conduction disease on the baseline ECG. In 23 patients (64%) family screening was not performed. Two of the 36 patients had undocumented syncope during follow-up. Univariate analysis showed no significant difference in event free survival between patients with or without consensus clinical diagnostic criteria.
CONCLUSIONS: In a significant number of patients with diagnostic ECG pattern the current diagnostic criteria for BS are not met. These patients have frequently spontaneous type I ECG and clinical signs of Brugada syndrome as paroxysmal atrial fibrillation or conduction disturbances. Our results suggest that in patients with a diagnostic type I ECG pattern the current clinical consensus diagnostic criteria have limited added diagnostic value.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Brugada syndrome; Consensus statement; Diagnosis

Mesh:

Year:  2012        PMID: 22805547     DOI: 10.1016/j.ijcard.2012.06.115

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  The Diagnosis, Risk Stratification, and Treatment of Brugada Syndrome.

Authors:  Johannes Steinfurt; Jürgen Biermann; Christoph Bode; Katja E Odening
Journal:  Dtsch Arztebl Int       Date:  2015-06-05       Impact factor: 5.594

Review 2.  The Brugada Syndrome - Diagnosis, Clinical Implications and Risk Stratification.

Authors:  Velislav N Batchvarov
Journal:  Eur Cardiol       Date:  2014-12

Review 3.  Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects.

Authors:  Charles Antzelevitch; Bence Patocskai
Journal:  Curr Probl Cardiol       Date:  2015-06-11       Impact factor: 5.200

Review 4.  Electrocardiographic methods for diagnosis and risk stratification in the Brugada syndrome.

Authors:  Abdulrahman Naseef; Elijah R Behr; Velislav N Batchvarov
Journal:  J Saudi Heart Assoc       Date:  2014-07-03

5.  Analysis of a Family with Brugada Syndrome and Sudden Cardiac Death Caused by a Novel Mutation of SCN5A.

Authors:  Yao-Bin Zhu; Jian-Hui Zhang; Yuan-Yuan Ji; Ya-Nan Hu; Han-Lu Wang; Dan-Dan Ruan; Xiao-Rong Meng; Xin-Fu Lin; Jie-Wei Luo; Wei Chen
Journal:  Cardiol Res Pract       Date:  2022-04-28       Impact factor: 1.990

Review 6.  Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis.

Authors:  Jakub Sroubek; Vincent Probst; Andrea Mazzanti; Pietro Delise; Jesus Castro Hevia; Kimie Ohkubo; Alessandro Zorzi; Jean Champagne; Anna Kostopoulou; Xiaoyan Yin; Carlo Napolitano; David J Milan; Arthur Wilde; Frederic Sacher; Martin Borggrefe; Patrick T Ellinor; George Theodorakis; Isabelle Nault; Domenico Corrado; Ichiro Watanabe; Charles Antzelevitch; Giuseppe Allocca; Silvia G Priori; Steven A Lubitz
Journal:  Circulation       Date:  2016-01-21       Impact factor: 29.690

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.